PrEP Watch is a clearinghouse for PrEP data, research, cost, access, implementation and advocacy efforts across the globe.
Countries are at varying stages of introducing daily oral PrEP using TDF/FTC, which is now recommended by WHO as an option for people at substantial risk of HIV. Some countries have national programs; others have smaller-scale programs; others aren’t offering PrEP at all.
In this map, yellow countries have some form of PrEP programming; blue countries do not. Check back for regular updates!
June 30, 2018
Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections. But the officials are hitting roadblocks — the drug's price tag, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients.
May 15, 2018
The US Food and Drug Administration has expanded the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV to include adolescents. Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.
May 9, 2018
New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP started taking the drug within 30 days — according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.
March 21, 2018
Australia's federal government has announced it will list an effective HIV prevention drug on the Pharmaceutical Benefits Scheme (PBS), starting next month. Health Minister Greg Hunt today confirmed that pre-exposure prophylaxis, known as PrEP, would be government subsidized from April 1.